Active substance
Allopurinol
- SFDA 12
- US FDA 35
- Health Canada 12
- US price lines 3
- NHS prices 3
- WHO EML 2
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NO-URIC 100 mg tablet | 100 mg | Tablet · Oral use | 50 Blister | SAR 16.30 | Generic · Prescription | EIPICO | Valid |
| NO-URIC TAB 300MG | 300 mg | Tablet · Oral use | 20 Blister | SAR 8.00 | Generic · Prescription | EIPICO | Valid |
| Purout 100 MG TABLETS | 100 mg | Tablet · Oral use | 100 Blister | SAR 22.75 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| Purout 300 MG TABLETS | 300 mg | Tablet · Oral use | 28 Blister | SAR 16.45 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| ZYLORIC 100MG TABLET | 100 mg | Tablet · Oral use | 50 Tablet Container | SAR 22.00 | Generic · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| APUROL 100MG TAB | 100 mg | Tablet · Oral use | 50 Blister | SAR 20.85 | NCE · Prescription | SIEGFRIED | Withdrawn by MAH · Not Marketed |
| PURINOL 100 MG | 100 mg | Tablet · Oral use | 100 Blister | SAR 17.20 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| PURINOL 300 MG | 300 mg | Tablet · Oral use | 30 Blister | SAR 11.45 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| UROQUAD TABS 100 MG | 100 mg | Tablet · Oral use | 50 Blister | SAR 19.55 | Generic · Prescription | ROCHE DIAGNOSTICS | Withdrawn by MAH · Not Marketed |
| UROQUAD TABS 300 MG | 300 mg | Tablet · Oral use | 100 Blister | SAR 95.35 | Generic · Prescription | ROCHE DIAGNOSTICS | Withdrawn by MAH · Not Marketed |
| ZYLORIC | 100 mg | Tablet · Oral use | 50 Blister | SAR 14.35 | Generic · Prescription | GLAXO SAUDI ARABIA | Withdrawn by regulatory authority · Not Marketed |
| ZYLORIC 100MG TABLET | 100 mg | Tablet · Oral use | 50 Blister | SAR 22.00 | Generic · Prescription | ASPEN | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ADULT ACUTE LYMPHOCYTIC LEUKEMIA (ALL)-ADVERSE REACTIONS MANAGEMENT; ADULT ACUTE MYELOID LEUKAEMIA (AML); BURKITT`S LYMPHOMA; CASTLEMAN DISEASE; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); DISORDERS OF PURINE AND PYRIMIDINE METABOLISM; FOLLICULAR LYMPHOMA; GOUT; HODGKIN'S LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; PEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)-ADVERSE REACTIONS MANAGEMENT; PEDIATRIC B-CELL LYMPHOMA; RENAL AND URETERIC STONES; T-CELL LYMPHOMA-RENAL TOXICITY
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZYLOPRIM | 100MG; 300MG; 200MG | tablet · oral | CASPER PHARMA LLC | Prescription | 19 Aug 1966 |
| ALLOPURINOL | 100MG | tablet · oral | WATSON LABS | Prescription | 28 Sep 1984 |
| ALLOPURINOL | 300MG | tablet · oral | WATSON LABS | Prescription | 28 Sep 1984 |
| ALLOPURINOL | 100MG; 300MG | tablet · oral | MYLAN | Prescription | 24 Oct 1986 |
| ALLOPURINOL | 300MG; 100MG | tablet · oral | SUN PHARM INDUSTRIES | Prescription | 9 Jan 1987 |
| LOPURIN | 300MG; 100MG | tablet · oral | DR REDDYS | Prescription | 2 Apr 1987 |
| ALOPRIM | EQ 500MG BASE/VIAL | injectable · injection | MYLAN | Prescription | 17 May 1996 |
| ALLOPURINOL | 100MG; 300MG | tablet · oral | PH HEALTH | Prescription | 27 Jun 2003 |
| ALLOPURINOL SODIUM | EQ 500MG BASE/VIAL | injectable · injection | HIKMA PHARMS | Prescription | 26 Aug 2004 |
| ALLOPURINOL | 100MG; 300MG | tablet · oral | CHARTWELL | Prescription | 8 Sep 2005 |
| ALLOPURINOL | 100MG; 300MG | tablet · oral | ACCORD HLTHCARE | Prescription | 6 May 2013 |
| ALLOPURINOL | 100MG; 300MG; 200MG | tablet · oral | REGCON HOLDINGS | Prescription | 28 Jul 2016 |
| ALLOPURINOL | 100MG; 300MG; 200MG | tablet · oral | ZYDUS PHARMS | Prescription | 12 Oct 2017 |
| ALLOPURINOL | 100MG; 300MG | tablet · oral | UNICHEM | Prescription | 12 Mar 2019 |
| ALLOPURINOL SODIUM | EQ 500MG BASE/VIAL | injectable · injection | GLAND | Prescription | 26 Jan 2022 |
| ALLOPURINOL | 100MG; 300MG; 200MG | tablet · oral | HARMAN FINOCHEM | Prescription | 7 Mar 2022 |
| ALLOPURINOL | 100MG; 300MG | tablet · oral | HETERO LABS LTD V | Prescription | 3 Aug 2023 |
| ALLOPURINOL | 100MG; 300MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 14 Apr 2025 |
| LOPURIN | 100MG; 300MG | tablet · oral | ABBOTT | Discontinued | 10 Jun 1980 |
| ALLOPURINOL | 300MG | tablet · oral | PURACAP PHARM | Discontinued | 10 Dec 1985 |
| ALLOPURINOL | 100MG | tablet · oral | PURACAP PHARM | Discontinued | 10 Dec 1985 |
| ALLOPURINOL | 100MG | tablet · oral | MUTUAL PHARM | Discontinued | 24 Dec 1985 |
| ALLOPURINOL | 300MG | tablet · oral | MUTUAL PHARM | Discontinued | 24 Dec 1985 |
| ALLOPURINOL | 100MG | tablet · oral | AIPING PHARM INC | Discontinued | 31 Dec 1985 |
| ALLOPURINOL | 300MG | tablet · oral | SANDOZ | Discontinued | 31 Dec 1985 |
10 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ALLOPURINOL-100 | 00555681 | 100 MG | TABLET · ORAL | PRO DOC LIMITEE |
| ALLOPURINOL-200 | 02130157 | 200 MG | TABLET · ORAL | PRO DOC LIMITEE |
| ALLOPURINOL-300 | 00555703 | 300 MG | TABLET · ORAL | PRO DOC LIMITEE |
| APO-ALLOPURINOL TABLETS | 00402796 | 300 MG | TABLET · ORAL | APOTEX INC |
| APO-ALLOPURINOL TABLETS | 00402818 | 100 MG | TABLET · ORAL | APOTEX INC |
| APO-ALLOPURINOL TABLETS | 00479799 | 200 MG | TABLET · ORAL | APOTEX INC |
| JAMP ALLOPURINOL | 02421593 | 100 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP ALLOPURINOL | 02421607 | 200 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP ALLOPURINOL | 02421615 | 300 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MAR-ALLOPURINOL | 02396327 | 100 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-ALLOPURINOL | 02396335 | 200 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-ALLOPURINOL | 02396343 | 300 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ALLOPURINOL 100 MG TABLET | $0.03154 | per EA | 23 Sep 2026 |
| US NADAC | ALLOPURINOL 200 MG TABLET | $1.84028 | per EA | 23 Sep 2026 |
| US NADAC | ALLOPURINOL 300 MG TABLET | $0.05218 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Allopurinol 100mg tablets | £0.67 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Allopurinol 200mg tablets | £14.24 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Allopurinol 300mg tablets | £0.81 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 29.1. Medicines used to treat gout · core
Gout
Oral > Solid: 100 mg - 8.2.5. Supportive medicines · complementary
Tumour lysis syndrome
Parenteral > General injections > IV: 500 mg (as sodium) powder for injection (EMLc) | Oral > Solid: 100 mg (EMLc); 300 mg (EMLc)
Safety signals and safety-related labeling changes
- US FDA 3 Apr 2024 ALLOPURINOL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations - US FDA 3 Apr 2024 ALLOPURINOL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations - US FDA 21 Sep 2023 ZYLOPRIM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 17 Feb 2022 ALOPRIM — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Allopurinol
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.